

## Prexigebersen sodium

**Cat. No.:** HY-153495A  
**Molecular Formula:** C<sub>177</sub>H<sub>206</sub>N<sub>63</sub>Na<sub>18</sub>O<sub>110</sub>P<sub>17</sub>  
**Molecular Weight:** 5916.25  
**Target:** Others  
**Pathway:** Others  
**Storage:** -20°C, sealed storage, away from moisture  
 \* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

### Prexigebersen (sodium)

#### SOLVENT & SOLUBILITY

##### In Vitro

H<sub>2</sub>O : ≥ 100 mg/mL (16.90 mM)  
 \* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM	0.1690 mL	0.8451 mL	1.6903 mL
	5 mM	0.0338 mL	0.1690 mL	0.3381 mL	
	10 mM	0.0169 mL	0.0845 mL	0.1690 mL	

Please refer to the solubility information to select the appropriate solvent.

#### BIOLOGICAL ACTIVITY

##### Description

Prexigebersen sodium is an antisense oligonucleotide designed to inhibit protein synthesis of Grb2 (growth factor receptor bound protein 2).

#### REFERENCES

- [1]. Maro Ohanian, Tara L. Lin, Ellen Ritchie, et al. Pierce, Ana Tari Ashizawa, Hagop Kantarjian, Jorge E. Cortes, Gail J. Roboz; Safety and Efficacy of Lower Intensity Induction Therapy with Intravenous Prexigebersen (BP1001) in Patients with High-Risk and Relapsed/Refractory Acute Myeloid Leukemia (AML). Blood 2021; 138 (Supplement 1): 1281.
- [2]. Tremblay G, Khalafaghian G, Legault J, Nielsen P, Bartlett A. Dual ligation hybridization assay for the specific determination of oligonucleotide therapeutics. Bioanalysis. 2011;3(5):499-508.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA